Immunological Principles of Adverse Drug Reactions
- 1 January 2000
- journal article
- review article
- Published by Springer Nature in Drug Safety
- Vol. 23 (6) , 483-507
- https://doi.org/10.2165/00002018-200023060-00002
Abstract
Adverse drug reactions account for between 2 to 5% of all hospital admissions and can prevent the administration of an otherwise effective therapeutic agent. Hypersensitivity or immune-mediated reactions, although less common, tend to be proportionately more serious. There is convincing evidence to implicate the immune system in the pathogenesis of hypersensitivity reactions. Our understanding of the way in which the immune system recognises drugs is based on the hapten hypothesis; the onset of hypersensitivity involves drug bioactivation, covalent binding to proteins, followed by uptake, antigen processing and T cell proliferation. Central to this hypothesis is the critical role of drug metabolism, with the balance between metabolic bioactivation and detoxification being one important component of individual susceptibility. The purpose of this review is to classify drug hypersensitivity reactions in terms of their clinical presentation, and also to consider recent advances in our understanding of the chemical, biochemical and, in particular, cellular immunological mechanisms of hypersensitivity. The following topics are reviewed: (i) drug disposition and cellular metabolism; (ii) mechanisms of antigen processing and presentation; (iii) the role of cytokines and co-stimulatory molecules in the induction and maintenance of a polarised immune response; and (iv) the application of the hapten hypothesis, danger hypothesis and serial triggering model to drug hypersensitivity. Agreater understanding of the mechanism(s) of hypersensitivity may identify novel therapeutic strategies and help to combat one of the more severe forms of adverse reactions to drugs.Keywords
This publication has 209 references indexed in Scilit:
- Transgenic mouse models of tumour angiogenesis: the angiogenic switch, its molecular controls, and prospects for preclinical therapeutic modelsEuropean Journal Of Cancer, 1996
- The role of macrophage- and dendritic cell-derived IL12 in Th1 phenotype developmentResearch in Immunology, 1995
- Cytotoxic activity of T cells and non-T cells from diclofenac-immunized mice against cultured syngeneic hepatocytes exposed to diclofenacHepatology, 1995
- Antigen processing: The gateway to the immune responseJournal of the American Academy of Dermatology, 1995
- Mechanisms of Unpredictable Adverse Drug ReactionsDrug Safety, 1994
- The Role of Active Metabolites in Drug ToxicityDrug Safety, 1994
- Diclofenac induced hepatitisDigestive Diseases and Sciences, 1993
- Drug-Induced Aplastic Anaemia and AgranulocytosisDrugs, 1986
- Ticrynafen-Associated Hepatic Injury: Analysis of 340 CasesHepatology, 1984
- Predisposition to Phenytoin Hepatotoxicity Assessed in VitroNew England Journal of Medicine, 1981